Latest Commercialisation News

Li-S Energy’s lithium-sulfur battery powered the Pegasus drone through an almost two-hour Queensland flight covering more than 75 kilometres. The result strengthens the technology’s aviation credentials, but the partners are still assessing commercialisation rather than announcing sales.

Ocean Sciences delivered a sharp increase in seaweed revenue during FY2026, but the audited report also records a A$1.612 million continuing-operations loss, A$2.319 million operating cash outflow and material uncertainty over its ability to continue as a going concern. The renamed ASX-listed group is now seeking up to A$3 million while building out its Indonesian platform.

Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.

AnteoTech has received $1.905 million from the Australian R&D Tax Incentive, providing fresh cash for its battery materials and life sciences commercialisation efforts. The rebate relates to eligible research conducted during the 2026 financial year.

New Frontier Minerals advanced its copper and rare earths portfolio during FY2026, but the annual report highlights a material uncertainty over its ability to continue as a going concern. The company ended the year with $1.23 million in cash after a $2.25 million placement and ongoing exploration spending.

Green360 Technologies has moved its MKX metakaolin product from testing into commercial supply, securing a binding agreement with Holcim Australia while cutting annualised fixed cash costs by about $1.6 million. The progress comes against a $4.25 million FY2026 loss, $3.93 million in operating cash outflows and an explicit need to prove the business can scale before its cash buffer runs down.

TradeWindow is targeting 13% to 18% revenue growth in FY27 and expects to approach EBITDA breakeven, while preparing to shift its primary listing from the NZX to the ASX. The freight software company also reported rising recurring revenue, stronger customer economics and NZ$4.0 million in cash at 30 June 2026.

Li-S Energy has narrowed its FY26 loss and reached several commercialisation milestones, including a 2C Power Cell, international shipping approvals and its first lithium foil sale. But the ASX battery developer still needs customer offtake and fresh funding before its proposed 1 GWh manufacturing expansion can become reality.

RMA Global has replaced its chief executive and moved to a new chair as it targets a simpler, faster and more profitable business across Australia, New Zealand and the United States. The company has set an EBITDA improvement objective for FY27, but has not yet quantified the plan.

Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.

Structural Monitoring Systems (ASX:SMN) delivered record FY26 revenue, a sharp lift in profit and $6.0 million of free cash flow as its avionics business outpaced contract manufacturing. The balance sheet is now free of bank debt, but the next leg of the story still depends on FAA approvals and converting CVM technology into commercial revenue.

Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.